CSL (ASX:CSL) share price up after new AstraZeneca advice

Amid a change in policy as to who can receive the AstraZeneca jab, CSL has declared it will continue making the vaccine even if Australia phases it out

| More on:
Woman getting vaccination

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is gaining today. This comes amid conflicting news from the Federal Government regarding the AstraZeneca plc (LSE: AZN) COVID-19 vaccine.

At the time of writing, the CSL share price is $289.62 – 0.42% higher than yesterday's close.

The AstraZeneca vaccine has been a crown jewel for the biotech company since September, when it announced it was to manufacture the vaccine in Melbourne. The CSL share price has often reacted to news of the vaccine's use in Australia.

Despite numerous changes to Australia's use of the AstraZeneca vaccine, CSL is determined to keep manufacturing it in Australia.

Late last night, Prime Minister Scott Morrison announced adults of any age can now request the AstraZeneca vaccine from their general practitioner.

This follows last week's news that the Federal Government plans to phase out the AstraZeneca vaccine in coming months.

Let's take a look at the latest news from CSL and of AstraZeneca's position in the vaccine rollout.

AstraZeneca and the vaccine rollout

In the latest news of the use of the AstraZeneca vaccine in Australia, the Federal Government is implementing a new no fault indemnity scheme for doctors giving COVID-19 vaccines.

This means all Australians able to be vaccinated can request to get the AstraZeneca jab through their general practitioner.

Previously, Australians aged over 60 were the only cohort able to receive the AstraZeneca shot due to its side effects, which include a one-in-200,000 chance of potentially deadly blood clots.

Word from the Prime Minister of flexibility in the age restrictions comes only days after the Federal Government released its vaccine distribution projections. Originally given to states and territories, the projections outlined the government's plans to phase out the AstraZeneca vaccine.

That document stated that from October, states and physicians wanting additional AstraZeneca vaccines will have to specifically request their availability.

In comments published by The Australian, CSL declared it won't stop manufacturing the embattled vaccine. It stated it may instead ship those produced in Melbourne overseas, as demand from other countries is thriving.

Chris Larkins, senior vice president of operations for CSL's vaccine producer Seqirus, was quoted by the publication as saying:

[The previous decision to restrict who can receive the AstraZeneca vaccine] is very much an Australian decision, based on what's happening in Australia and the lack of any sort of real transmission of Covid, we've had governments calling us up from around the world saying 'we'll take it'.

Today may be an interesting day for the CSL share price. Major news of Australia's use of the AstraZeneca vaccine often inspires excitement from the market.

CSL share price snapshot

The CSL share price needs all the good news it can get after battling a tough 2021 on the ASX.

Currently, shares in CSL have gained just 1.5% year to date. However, the CSL share price has fallen 0.1% since this time last year.

The company has a market capitalisation of around $131 billion, with approximately 455 million shares outstanding.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Healthcare Shares

ResMed shares jump 8% on stellar start to FY25

This high-quality company continues to deliver the goods.

Read more »

Senior woman with caregiver in the garden
Healthcare Shares

A 'golden era' is coming for these ASX healthcare shares

Here's why Blackwattle Partners sees tailwinds ahead for one particular category of healthcare shares.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is rising on big FDA news

Some big news is giving this stock a major lift on Thursday.

Read more »